MSB Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients - 31st May 2022, 10:03am

annb0t

annb0t

Top 20
MSB Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients
Price Sensitive: N
Date: 31st May 2022, 10:03am

>>> Read announcement: Google: MSB Market Announcements
 
You must log in or register to reply here.

Similar threads

annb0t
MSB Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L - 8th Mar 2023, 10:35am
Replies
0
Views
216
annb0t
annb0t
annb0t
MSB Ann: Remestemcel Clinical and Potency Studies Presented at Tandem - 17th Feb 2023, 9:54am
Replies
0
Views
135
annb0t
annb0t
annb0t
MSB Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel - 23rd Nov 2022, 8:54am
Replies
0
Views
174
annb0t
annb0t
annb0t
MSB Ann: Quarterly Activities/Appendix 4C Cash Flow Report - 31st Oct 2023, 10:06am
Replies
0
Views
96
annb0t
annb0t
annb0t
MSB Ann: Annual Report to Shareholders - 30th Oct 2023, 9:02am
Replies
0
Views
82
annb0t
annb0t
Top Bottom